• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Malaysia Pharmaceuticals and Healthcare Report Q2 2011 - Product Image

Malaysia Pharmaceuticals and Healthcare Report Q2 2011

  • Published: March 2011
  • Region: Malaysia
  • 112 Pages
  • Business Monitor International


  • Bumimedic Sdn Bhd
  • Hovid
  • Merck & Co
  • Novartis
  • Pharmaniaga
  • Ranbaxy Malaysia
  • MORE

Business Monitor International's Malaysia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Malaysia's pharmaceuticals and healthcare industry.

Product Description
The Malaysia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)’s 5 and 10-year forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI’s Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.

Key Benefits
- Benchmark BMI’s independent 5 and 10-year pharmaceutical and healthcare industry forecasts on Malaysia to test other views – a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical READ MORE >

Executive Summary

SWOT Analysis
- Malaysia Pharmaceuticals And Healthcare Industry SWOT
- Malaysia Political SWOT
- Malaysia Economic SWOT
- Malaysia Business Environment SWOT

Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q211
- Rewards
- Risks

Malaysia – Market Summary
- Regulatory Regime
- Bioequivalence
- Pharmaceutical And Medical Advertising
- Labelling Requirements
- Recent Regulatory Developments
- Intellectual Property Regime
- Counterfeit Pharmaceuticals
- Compulsory Licensing
- Free Trade Agreements
- Pricing And Reimbursement

Industry Trends And Developments
- Epidemiology
- Table: 10 Leading Causes Of Death In Ministry of Health Hospitals, 2005
- Non-Communicable Disease
- Communicable Disease
- Healthcare Sector
- Healthcare Sector Funding
- Medical Tourism
- Biotechnology And Research
- Table: Key Points Of The Malaysian National Biotechnology Policy
- Table: The Benefits Of Conducting Biotechnology Research In Malaysia
- Recent Biotechnology Developments
- Clinical Trials
- Recent Developments in the Clinical Trials Industry
- Medical Devices
- Leading Medical Device Players
- Recent Developments In The Medical Devices Industry

Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors – Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors – Macroeconomic
- Table: Malaysia – Economic Activity, 2006-2015
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks To BMI’s Forecast Scenario

Competitive Landscape Analysis
- Domestic Pharmaceutical Industry
- Foreign Pharmaceutical Industry
- Pharmaceutical Demand
- Recent Company Activities
- Table: Leading Malaysian Pharmaceutical And Healthcare Companies
- Halal Medicine
- Traditional Medicine
- Pharmaceutical Distribution

Company Profiles
- Leading Domestic Manufacturers
- Pharmaniaga
- Prime Pharmaceutical
- Bumimedic Sdn. Bhd
- Hovid
- Chemical Company of Malaysia (CCM)
- Kotra Pharma
- Multinational Companies
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Merck & Co
- Sanofi-Aventis
- Ranbaxy Malaysia

Country Snapshot: Malaysia Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2000-2003
- Table: Vital Statistics, 2005-2030

BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources

Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTS, give a complete overview of market climate.

Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation, advertising, as well as an analysis of the overall regulatory burden.

Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI 5 and 10-Year Industry Forecast
5 and 10-year forecasts for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per ‘000 population), doctors (per ‘000 population), birth and mortality rate (per ‘000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape
Competitive landscape provides comparative company analyses and rankings by US$ sales, % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles
Examining the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT (Strengths, Weaknesses, Opportunities and Threats) analyses. Latest financial and operating statistics and key company developments are also incorporated within our company profiles, enabling a full evaluation of recent company performance and future growth prospects.

- Pharmaniaga
- Prime Pharmaceutical
- Bumimedic Sdn Bhd
- Hovid
- Chemical Company of Malaysia (CCM)
- Kotra Pharma
- Multinational Companies
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Merck & Co
- Sanofi-Aventis
- Ranbaxy Malaysia

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos